Using CE and FDA Approvals for Malaysian Medical Device Registration

1. Key takeaways

A CE mark or an FDA clearance does not exempt a device from Malaysian registration, but it can simplify the assessment. Where the manufacturer holds an approval from a recognised country, the file may proceed by way of the verification route, in which the CAB verifies the existing evidence rather than conducting a full assessment. The MDA registration step cannot be skipped under any circumstances, and the verification route does not change the requirement to submit, pay and be registered. The distinction between exemption and simplification is the single most important point for manufacturers arriving from the European or American regulatory systems, because it determines both the documents required and the assumptions that can safely be carried across.

• Foreign approval enables simplification through the verification route; it does not create an exemption.
• The CAB verifies existing conformity evidence, but the MDA registration step always remains.
• CE certificates qualify only where the certificate type falls within Table 1 of the Circular.
• A self-declared Declaration of Conformity does not meet the conditions for verification.
• FDA 510(k) clearance letters and PMA letters are within the recognised list, but 510(k) exempt products are not eligible and require full assessment.
• Test reports and clinical data can be reused; classification, grouping, labelling language, AR and establishment licence, and PMS arrangements must be localised.
• European classes I, IIa, IIb and III cannot be mapped directly to Malaysian classes A, B, C and D.

2. Legal basis

The verification route is established by Circular Letter MDA No. 1/2025, whose Table 1 lists the recognised approval types and whose paragraph (12) addresses the treatment of submissions relying on those approvals. MDA/GD/0068 and MDA/GD/0070 provide the supporting guidance on the evidence expected, and the Third Schedule to the Medical Device Regulations 2012 supplies the four-element assessment structure within which verification takes place. The Circular distinguishes between approval types rather than between jurisdictions in general terms, which is why the identity of the certificate matters more than the country that issued it. Under the Medical Devices Directive, the qualifying routes include Annex II Section 3 and Section 4 and Annex V. Under the In Vitro Diagnostic Directive, the distinction turns on List A and List B and on whether the device is self-testing or non-self-testing. Under the Medical Device Regulation and the In Vitro Diagnostic Regulation, the submission must correspond to a notified body certificate or to a EUDAMED registration. A route built on a self-declared Declaration of Conformity falls outside these categories and therefore does not satisfy the verification conditions.

3. Expert insights

The practical question is never whether a manufacturer has a CE certificate, but what kind of certificate it is. A certificate issued under a notified body route that appears in Table 1 supports verification. A self-declared DoC, however well constructed, does not, because there is no third-party conformity assessment behind it for the CAB to verify. The same logic applies to FDA documents: a 510(k) clearance letter and a PMA letter sit within the recognised list, while a product that is 510(k) exempt has no clearance letter at all and must therefore follow the full assessment path. Manufacturers sometimes assume that exemption from FDA premarket review implies a lighter Malaysian route; the opposite is true in this specific case.

The boundary of evidence reuse is the second area where expectations diverge from the rules. Test reports and clinical data travel well, because they describe the device rather than the jurisdiction. Everything that describes the regulatory arrangement does not travel: classification, grouping, labelling language, the AR and establishment licence, and PMS arrangements must all be built to Malaysian requirements. The classification point deserves emphasis because it is the source of the most consequential error. The European classification logic addresses a different set of risks and applies different rules, so a Class IIa device is not automatically a Class B device in Malaysia. The Malaysian class must be argued from the First Schedule on its own terms, and the resulting class determines the assessment route, the fee and the evidence expected.

Multi-country sequencing is where the leverage becomes strategic rather than tactical. A commonly used industry path runs from European MDR approval, to Singapore HSA, and then to the Malaysian verification route, using a single evidence baseline that is rolled forward from one submission to the next. The sequence is not fixed; it can be adjusted according to the size of the target market and the certificates already held. What remains constant is that each jurisdiction contributes evidence to the next, so the order should be chosen to maximise the value of what has already been assessed rather than to follow a default template.

4. Practical recommendations

• Run a gap analysis between the CE or FDA dossier and the CSDT before planning the submission, rather than after the CAB has raised questions.
• List the Malaysian-specific requirements separately, including EPSP item-by-item comparison and PMS history, since these are the elements foreign dossiers rarely contain in usable form.
• Start the gap closure roughly three to four weeks ahead of the planned CAB engagement, so that missing items do not stall the assessment.
• Identify the exact certificate type for each CE certificate and confirm it against Table 1, rather than relying on the presence of a CE mark.
• Confirm whether an FDA document is a 510(k) clearance letter or a PMA letter, and treat 510(k) exempt products as requiring full assessment.
• Re-derive the Malaysian classification from the First Schedule and document the reasoning, instead of mapping from the European class.
• Localise labelling language, AR and establishment licence arrangements, and PMS commitments as separate workstreams with their own owners.

5. Verification checklist

• □ Table 1 of Circular Letter MDA No. 1/2025, including paragraph (12), has been reviewed for the specific approval type held.
• □ The Third Schedule to the Medical Device Regulations 2012 has been checked for the four assessment elements.
• □ MDA/GD/0068 and MDA/GD/0070 have been consulted for the evidence expected in a verification submission.
• □ The multi-country sequencing described in the plan is identified as common industry practice rather than a regulatory requirement.
• □ Any reused evidence is tested against Malaysian classification, grouping, labelling and PMS requirements before being carried forward.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com